Abstract: The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with an isolated enveloped virus, having a membrane, to inactivate the membrane of the isolated enveloped virus. The subject is then treated with the enveloped virus having an inactivated membrane to vaccinate the subject against the enveloped virus. Further disclosed is an ex vivo vaccine composition including the compound of Formula (I) and an enveloped virus.

Abstract: Methods of using the formulations disclosed herein to treat or prevent a broad spectrum of enveloped viruses are provided. In particular, a method of treating or preventing a disease state caused by an enveloped type virus can include agents of a formula wherein R1, is selected from the group consisting of OH, OR6, NHR6, and NR6R7 where R6 and R7 are selected from the group consisting of alkyl, aryl, methyl and heteroaryl; R2 is selected from the groups consisting of OR6, acyl, alky, aryl, and sulfonyl; R3 is selected from the group consisting of OR6 alkyl, aryl, substituted aryl, and heteroaryl; R4 and R5 are independently selected from the groups consisting of hydrogen, methyl or alkyl, substituted alkyl, aryl, and substituted aryl; and whereby, administration of the compound allows for the treatment of enveloped viruses.

Abstract: Methods of using the formulations disclosed herein to treat or prevent a broad spectrum of enveloped viruses are provided. In particular, a method of treating or preventing a disease state caused by an enveloped type virus can include agents of a formula wherein R1, is selected from the group consisting of OH, OR6, NHR6, and NR6R7 where R6 and R7 are selected from the group consisting of alkyl, aryl, methyl and heteroaryl; R2 is selected from the groups consisting of OR6, acyl, alky, aryl, and sulfonyl; R3 is selected from the group consisting of OR6 alkyl, aryl, substituted aryl, and heteroaryl; R4 and R5 are independently selected from the groups consisting of hydrogen, methyl or alkyl, substituted alkyl, aryl, and substituted aryl; and whereby, administration of the compound allows for the treatment of enveloped viruses.